View Item 

Show simple item record

Tenofovir‐based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir
dc.contributor.authorLu, L.en_US
dc.contributor.authorYip, B.en_US
dc.contributor.authorTrinh, H.en_US
dc.contributor.authorPan, C. Q.en_US
dc.contributor.authorHan, S.‐h. B.en_US
dc.contributor.authorWong, C. C.en_US
dc.contributor.authorLi, J.en_US
dc.contributor.authorChan, S.en_US
dc.contributor.authorKrishnan, G.en_US
dc.contributor.authorWong, C. C.en_US
dc.contributor.authorNguyen, M. H.en_US
dc.date.accessioned2015-08-05T16:47:13Z
dc.date.available2016-09-06T15:43:59Zen
dc.date.issued2015-08en_US
dc.identifier.citationLu, L.; Yip, B.; Trinh, H.; Pan, C. Q.; Han, S.‐h. B. ; Wong, C. C.; Li, J.; Chan, S.; Krishnan, G.; Wong, C. C.; Nguyen, M. H. (2015). "Tenofovirâ based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir." Journal of Viral Hepatitis (8): 675-681.en_US
dc.identifier.issn1352-0504en_US
dc.identifier.issn1365-2893en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/112234
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherswitchen_US
dc.subject.othertenofoviren_US
dc.subject.otherchronic hepatitis Ben_US
dc.subject.otherentecaviren_US
dc.subject.otherpartial virological responseen_US
dc.titleTenofovir‐based alternate therapies for chronic hepatitis B patients with partial virological response to entecaviren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/112234/1/jvh12368.pdf
dc.identifier.doi10.1111/jvh.12368en_US
dc.identifier.sourceJournal of Viral Hepatitisen_US
dc.identifier.citedreferenceHa NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily. J Clin Gastroenterol 2013; 47: 461 – 465.en_US
dc.identifier.citedreferenceHepatitis B [Internet]. [Place unknown]: World Health Organization; [Date unknown] [updated 2013 July]. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ (accessed 6 June 2014).en_US
dc.identifier.citedreferenceBeasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942 – 1956.en_US
dc.identifier.citedreferenceLok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661 – 662.en_US
dc.identifier.citedreferenceIloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678 – 686.en_US
dc.identifier.citedreferenceLiaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11: 669 – 679.en_US
dc.identifier.citedreferenceMommeja‐Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309 – 1319.en_US
dc.identifier.citedreferenceWoo G, Tomlinson G, Nishikawa Y et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta‐analyses. Gastroenterology 2010; 139: 1218 – 1229.en_US
dc.identifier.citedreferenceKeeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315 – 1341.en_US
dc.identifier.citedreferenceLuo J, Li X, Wu Y et al. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide‐Naïve chronic hepatitis B patients in real life. Int J Med Sci 2013; 10: 427 – 433.en_US
dc.identifier.citedreferenceGish R, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg‐positive chronic hepatitis B. Gastroenterology 2007; 133: 1437 – 1444.en_US
dc.identifier.citedreferenceColonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656 – 1665.en_US
dc.identifier.citedreferenceBartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162 – 170.en_US
dc.identifier.citedreferenceChen CH, Hu TH, Hung CH, Wang JH, Lu SN, Lee CM. Antiviral effect of entecavir in nucleos(t)ide analogue‐naïve and nucleos(t)ide analogue‐experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. J Viral Hepat 2014; 21: e55 – e64.en_US
dc.identifier.citedreferencePan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat 2012; 19: 213 – 219.en_US
dc.identifier.citedreferencePetersen J, Ratziu V, Buti M et al. Entecavir plus tenofovir combination as rescue therapy in pre‐treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56: 520 – 526.en_US
dc.identifier.citedreferenceYip B, Chaung K, Wong CR et al. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci 2012; 57: 3011 – 3016.en_US
dc.identifier.citedreferenceEASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167 – 185.en_US
dc.identifier.citedreferenceZoutendijk R, Reijnders JG, Brown A et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011; 54: 443 – 451.en_US
dc.identifier.citedreferenceYang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology 2014; 59: 1303 – 1310.en_US
dc.identifier.citedreferenceHa NB, Ha NB, Garcia RT et al. Medication nonadherence with long‐term management of patients with hepatitis B e antigen‐negative chronic hepatitis B. Dig Dis Sci 2011; 56: 2423 – 2431.en_US
dc.identifier.citedreferenceHongthanakorn C, Chotiyaputta W, Oberhelman K et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53: 1854 – 1863.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jvh12368.pdf
Size:
207.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.